

Jubilant Life Sciences Limited

1A, Sector 16A, Noida – 201301, India Tel.: +91 120 4361000 http://www.jubl.com

PRESS RELEASE
Noida, Thursday, March 26, 2020

Jubilant Life Sciences gives free hand sanitizers to support fight against COVID-19

Jubilant Life Sciences Limited, a Jubilant Bhartia Group company, announced that its research and development team has developed formulation for hand sanitizer using its own produced Ethanol. The company got necessary approvals & has quickly realigned its manufacturing facility to start producing hand sanitizers at a short notice. This was made possible due to support by Government of Uttar Pradesh & its departments, who gave all the necessary approvals in record time, including Food Safety & Drug Administration, the Excise Department and the Uttar Pradesh Pollution Control Board.

Jubilant Life Sciences has started supplying, free of cost, these hand sanitizers to Governments both at the national & the state level. Noida Administration, Government Hospital, Municipal, District Administration, Police Personnel at Jyotiba Phuley Nagar and Gautam Budha Nagar and the healthcare staff & volunteers working at All India Institute of Medical Sciences, Delhi have received the first instalment.

Government of India has taken commendable actions against the spread of COVID-19. Jubilant Bhartia Group companies are committed to support these measures through the supply of hand sanitizers to the healthcare workers in the hospitals and in the field, to control the spread of this pandemic.

About Jubilant Life Sciences Limited

Jubilant Life Sciences Limited is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery & Development Solutions businesses. Pharma business through Jubilant Pharma Limited Singapore (JPL) is engaged in manufacturing and supply of Radiopharmaceuticals with a network of over 50 radio-pharmacies in the US, Allergy Therapy Products, Contract Manufacturing of Sterile Injectibles & Non-sterile products, APIs and Solid Dosage Formulations through six USFDA approved manufacturing facilities in the US, Canada and India. The Life Science Ingredients segment, is engaged in Specialty Intermediates, Nutritional Products and Life Science Chemicals through five manufacturing facilities in India. Drug Discovery & Development Solutions comprises Drug Discovery Services (DDS) business through Jubilant Biosys Limited & Jubilant Chemsys Limited and Proprietary Drug Discovery business through Jubilant Therapeutics. DDS provides innovation and collaborative research through two world class research centers in Bangalore and Noida in India and Proprietary Drug Discovery is an innovative biopharmaceutical company developing breakthrough therapies in the area of oncology and auto-immune disorders. Jubilant Life Sciences Limited has a team of around 8,000 multicultural people across the globe and is committed to deliver value to its customers across over 100 countries. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals and life sciences companies globally. For more info: www.jubl.com.



For more information, please contact:

For Investors

Ravi Agrawal / Vineet Mayer Jubilant Life Sciences Limited E-mail: ravi.agrawal@jubl.com

Siddharth Rangnekar CDR India

E-mail: siddharth@cdr-india.com

For Media

Sudhakar Safaya Jubilant Life Sciences Limited E-mail: sudhakar.safaya@jubl.com

vineet.mayer@jubl.com

Desiree Crasto Madison Public Relations

E-mail: desiree.crasto@madisonpr.in
Phone number: +91 9819541498

Disclaimer

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.